# A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.

> **NCT07010107** · PHASE3 · RECRUITING · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 500 (estimated)

## Conditions studied

- Reflux Esophagitis (RE)

## Interventions

- **DRUG:** Anaprazole + Rabeprazole placebo
- **DRUG:** Rabeprazole + Anaprazole placebo

## Key facts

- **NCT ID:** NCT07010107
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-04
- **Final completion:** 2026-08
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010107, "A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07010107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*